GSK IMPORTANT DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages GSK plc Investors to Secure Counsel Before Important April 7 Deadline in Securities Class Action – GSK

Core Viewpoint - Rosen Law Firm is reminding purchasers of GSK plc American Depositary Receipts (ADRs) of the upcoming lead plaintiff deadline for a class action lawsuit related to the company's alleged misrepresentations regarding Zantac [1][2]. Group 1: Class Action Details - The class action pertains to GSK ADRs purchased between February 5, 2020, and August 14, 2022, with a lead plaintiff deadline set for April 7, 2025 [1][2]. - Investors who purchased GSK ADRs during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. Group 2: Allegations Against GSK - The complaint alleges that GSK misled investors by claiming that the withdrawal of Zantac was based on available information and regulatory correspondence, while in reality, GSK had known about the source of NDMA for nearly 40 years [4][5]. - GSK assured investors that there was no causal link between ranitidine therapy and cancer, which the lawsuit claims was materially false or misleading [4][5]. - The lawsuit asserts that GSK concealed an internal study that indicated potential liability to Zantac users, leading to investor damages when the truth was revealed [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [3]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been recognized as a leader in securities class action settlements [3].